Details from a US government study and a separate trial conducted by the company itself suggest remdesivir may become the first medication approved to treat the novel coronavirus Gilead Sciences Inc.
may spend $1 billion on its breakthrough new treatment for Covid-19 this year alone, Chief Executive Officer Daniel O’Day said.
How much revenue -- if any -- the company expects to generate is another matter. Details from a U.S. government study and a separate trial conducted by the company itself suggest remdesivir may become the first medication approved to treat the novel coronavirus, which has sickened 3.2 million people worldwide and killed 233,000.
Read more on livemint.com